Tvardi Therapeutics, Inc. (TVRD): Shareholders' Equity
$20.95M
As of 2025-12-31
$8.38M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.95M | n/m | 2026-03-31, Balance as of period end |
| 2024-12-31 | -$91.13M | n/c | 2026-03-31, Balance as of period end |
| 2023-12-31 | $57.09M | -64.0% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $158.78M | -30.2% | 2025-03-11, Balance as of period end |
| 2021-12-31 | $227.52M | -8.6% | 2024-03-06, Balance as of period end |
| 2020-12-31 | $249.00M | +33.4% | 2023-03-06, Balance as of period end |
| 2019-12-31 | $186.71M | +39.7% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $133.63M | +54.0% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $86.78M | +71.1% | 2020-02-27, Balance as of period end |
| 2016-12-31 | $50.73M | -51.7% | 2019-03-12, Balance as of period end |
| 2015-12-31 | $105.04M | +103.3% | 2018-03-15, Balance as of period end |
| 2014-12-31 | $51.66M | n/m | 2017-03-10, Balance as of period end |
| 2013-12-31 | -$54.08M | n/m | 2016-03-11, Balance as of period end |
| 2012-12-31 | -$58.13M | n/a | 2015-03-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $20.95M | n/m |
| Equillium, Inc. (EQ) | 2025-12-31 | $28.60M | +50.0% |
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $18.41M | +89.6% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $2.84M | n/m |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $16.80M | +562.6% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $22.74M | +193.5% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $9.25M | n/a |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $27.77M | -46.7% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $23.04M | -2.0% |
Compare TVRD, EQ, NVCT, DARE side by side · Screen every company in Pharmaceutical Preparations ↗